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Abstract
The effects of three different adjuvants, mineral oil, Montanide™ ISA 70M VG, and Montanide™ ISA 206 VG, were
evaluated on reverse genetics H5N3 avian influenza virus cell cultured vaccine. The immune results of SPF chickens
after challenging with highly pathogenic avian influenza (HPAI) virus demonstrated that mineral oil adjuvant group
and 70M adjuvant group provided 100% protection efficiency, but 206 adjuvant group provided only 40%.
Statistical analysis indicated that the protection effects of mineral oil adjuvant group and the 70M adjuvant showed
no significant difference to each other, but with significant difference to 206 adjuvant group. All three groups
could induce high titres of antibody after immunizing SPF ducks, but there was no significant difference among
them. The immunization effect of 70M adjuvant group on SPF chickens were the best and showed significant
difference compared with optimized 70Mi Montanide™ eight series adjuvants groups. These results suggest that
70M adjuvant could be a novel adjuvant for preparing avian influenza vaccine.
Introduction
H5 subtype highly pathogenic avian influenza (HPAI)
viruses could cause severe disease and enormous eco-
nomical loss to poultry farms. They could also cross
the species barrier to infect mammals. In particular,
the direct transmission of avian influenza viruses to
humans without the pigs as “vessel” might be ser-
iously endangered the poultry industry and human
health [1-3]. It is very important to strengthen bird
influenza surveillance, prevention and control work.
The main control strategies for H5N1 subtype HPAI
involve increased bio-security, surveillance, and vacci-
nation, however, the vaccination is an effective and
economic strategy in controlling the prevalence of
this disastrous disease. At present, the widely used
conventional inactivated H5 subtype bird influenza
virus is from allantoic fluids of embryonated chicken
eggs. It is necessary to solve many problems in vac-
cine development, including the difficulty in vaccine
strains construction by conventional method [4], the
serious byproducts pollution from embryonated
chicken eggs in vaccines production progress, and the
difficulty to differentiate nature infected and routine
immunized birds. A new type of vaccine production
system which could replace embryonated chicken eggs
and differentiate between the infected and the immu-
nized birds is urgent need.
The modern molecular biological techniques provide a
new approach for new type of influenza vaccine design
[5]. Compare to traditional vaccine development, the
new influenza vaccine development trend should have
the same or no less protective effects, saving times in
the vaccine production process, alleviating environmen-
tal pollution, providing a higher levels of bio-security.
The reverse genetics H5N3 (rH5N3) avian influenza
vaccine strain was successfully constructed by the
reverse genetics technique [6]. The prepared rH5N3
vaccine strain, which could discriminate the infected
birds from the immunized birds by N3 marker [7,8], can
replicate effectively in MDCK cell lines [6]. To further
promote vaccine effects and scan the optimal adjuvant,
the rH5N3 virus was used in this study to evaluate dif-
ferent adjuvants.
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Materials and methods
Virus
The rH5N3 avian influenza vaccine strain was previously
constructed by reverse genetics [6]. Briefly, the six inter-
nal genes came from high-yield influenza virus A/
Goose/Dalian/3/2001 (H9N2), hemagglutinin (HA) gene
from A/Goose/HLJ/QFY/2004(H5N1), and neuramini-
dase (NA) gene from A/Duck/Germany/1215/73(H2N3)
reference strain. The HA gene was modified by the dele-
tion of four basic amino acids of the connecting peptide
between HA1 and HA2. The rH5N3 was generated by
co-transfection to mixed Madin-Darby canine kidney
(MDCK) cell lines and Human embryonic kidney (HEK)
293T cell lines. Stock virus was made with MDCK cells.
All experiments with H5N1 subtype influenza virus
were performed in Bio-Safety Levels 3+ containment
laboratory.
Birds
The three-week-old specific pathogen free (SPF) White
Leghorn chickens and SPF ducks were used in this experi-
ment offered by Experimental Animal Center of the Har-
bin Veterinary Research Institute. All animals were housed
in the stainless steel isolation cabinets that were ventilated
under negative pressure with HEPA-filtered air.
HI antigen and adjuvants
The H5 subtype avian influenza HI antigen and domestic
mineral oil adjuvant provided by Harbin Wei Ke Biotech-
nology Development Company of the HVRI. Montanide™
ISA 206 VG adjuvant, Montanide™ ISA 70M VG adju-
vant and Montanide™ ISA 70 essai Mi (i = 1-8) adjuvant
provided by France Seppic Shanghai Branch [9].
Preparation of vaccine
The cell-cultured rH5N3 avian influenza virus was inac-
tivated by 1‰ formalin. The inactivated virus mixed
with mineral oil adjuvant at 1:2 (Vol/Vol) and then
emulsified as conventional methods. 70M, 70Mi, and
206 adjuvant vaccine prepared as described by Seppic
protocols, respectively. Briefly, inactivated virus mixed
with 70M and 70Mi adjuvant at a ratio of 2.6:7.4 (v/v),
with 206 adjuvant at a ratio of 4.6:5.4 (v/v), respectively,
and then emulsified as described by Seppic protocols.
Immunization of animals
Immunization and challenge experiments were per-
formed in accordance with instructions in the OIE man-
ual to evaluate the effects of different adjuvant. The
experiments were divided three parts. In the first part,
all the fifty three-week-old SPF White Leghorn chickens
were randomly divided into five groups equally. Three
groups were immunized with mineral oil adjuvant
vaccine, 70M adjuvant vaccine, and 206 vaccine adju-
vant, respectively, the fourth group vaccinated only with
inactivated virus without adjuvant, the fifth mock group
injected with sterile phosphate-buffered saline (PBS).
SPF chickens from group 1 to 4 vaccinated subcuta-
neously in the neck with 10 μg/ml per chicken, and the
mock group vaccinated with 0.3 ml PBS (Table 1).
In part II experiments, thirty two three-week-old SPF
ducks were randomly divided into four groups of eight
birds each. Three groups were immunized with mineral
oil adjuvant vaccine, 70M adjuvant vaccine, and 206
adjuvant vaccine with 0.25 ml antigen per duck in the
neck, respectively. Group four as control injected with
0.5 ml PBS per duck. The boosting immunization was
conducted three weeks after primary immunization with
the same dose (Table 1).
In part III experiments, one hundred three-week-old
SPF chickens were randomly divided into ten groups of
ten birds. The first group was immunized with 70M
adjuvant vaccine. The groups 2-9 inoculated with 70Mi
(i = 1-8) adjuvant vaccine, respectively. SPF chickens
from groups 2-9 vaccinated same as to the first group.
Group 10 as control injected with 0.3 ml PBS each
chicken. The boosting immunization was performed
three weeks followed primary immunization with the
same dose (Table 1).
Monitoring of antibody titres
2, 3, 4, 6, 8, and 13 weeks after primary immunization,
all birds were bled for sera collecting. 0 day before
initial immunization, 2 weeks after primary immuniza-
tion, 3 and 6 weeks after boosting immunization, all
ducks were bled for sera collecting. The dynamic
changes of antibody titres were detected by HI test.
Challenge
Each chicken from five groups of part I and ten groups
of part III were challenged with H5N1 HPAI virus A/
Gs/HLJ/QFY/04(H5N1) 106 EID50 through intranasal
and eye drop administration. Adjuvant effects for
rH5N3 vaccines were evaluated after 13 weeks post-vac-
cination. Morbidity and mortality was observed daily for
10 days. Cloaca and throat swabs of birds of part III
were collected at 3, 7, and 10 days post-challenge for
virus detection.
Statistical analysis
A Student t-test was used to analyze the results of the
HI assay for the levels of antibodies.
Results
Dynamic changes of antibody titres
The antibody titres of five groups chickens at 2, 3, 4, 6,
8, and 13 weeks post-vaccination in part I were
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measured by HI test (Figure 1). There was no significant
difference (P > 0.05) between mineral oil adjuvant group
and 70M adjuvant group from statistical analysis, but
there were significant differences (P < 0.01) when
mineral oil adjuvant group or 70M adjuvant group com-
pared with 206 adjuvant group. The antibody titre from
70M adjuvant group was higher than that of the mineral
oil adjuvant group. The chicken of control groups did
not elicit HI antibody.
0 day before initial immunization, 3 weeks after pri-
mary immunization, 3 and 6 weeks post boosting immu-
nization, the ducks antibody titres of four groups in part
II were detected by HI test (Figure 2). The results indi-
cated that all three groups can induce good immune
response and produce similar level of HI antibody.
There were no statistically significant differences (P >
0.05) among mineral oil adjuvant group, 70M adjuvant
Figure 1 Antibody responses to mineral oil-adjuvanted, 70M-
adjuvanted, 206-adjuvanted or non-adjuvanted rH5N3 vaccines
in SPF chickens.
Table 1 Experiment design
Parts Birds group Boosting date
a






206 2, 3, 4, 6, 8, and 13 w after
primary immunization







Part II SPF ducks rH5N3
Antigen
3 w p.v.d 0 day before initial
immunization,






70 Mi(i = 1-8) 3 w p.v. 2, 3, 4, 6, 8, and 13 w after
primary immunization
13 w after primary
immunization
3, 7, and 10 days p.c.e
PBS
a Group I didn’t perform boosting immunization
b Group II didn’t conduct challenge experiments.
c Group I didn’t collected trachea and cloaca swabs after challenge.
Figure 2 Antibody responses to mineral oil-adjuvanted, 70M-
adjuvanted, 206-adjuvanted, and non-adjuvanted rH5N3
vaccines in SPF ducks.
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group, and 206 adjuvant group. The ducks of control
groups did not elicit HI antibody.
The antibody titres of 2, 3, 4, 6, 8, and 13 weeks post-
immunization in part III chickens immunized with 70M
or 70Mi (i = 1-8) adjuvant vaccine were monitored by
HI test (Figure 3). There are statistically significant dif-
ferences (P < 0.01) between 70M adjuvant group and
other 70Mi (i = 1-8) groups, but each of nine groups
showed no statistically distinguishable differences (P >
0.05) compared with 206 adjuvant group. The chicken
of control groups did not elicit HI antibody.
Birds had inflammation at injection site in mineral oil
adjuvant group, but other groups did not show any clin-
ical and pathological signs.
Study of challenge and protection
After challenge with A/Gs/HLJ/QFY/04 (H5N1) virulent
viruses, chickens from mineral oil adjuvant and 70 M
adjuvant vaccine groups in part I showed no sign of dis-
ease and no birds died in this experiment. Mineral oil
adjuvant vaccine or 70 M adjuvant vaccine were able to
provide 100% protective efficiency to SPF chickens
(Table 2). However, 206 adjuvant vaccine group and
antigen without adjuvant group provide only 50% or
even less protective efficiency to SPF chickens. Chickens
from the control group were dead in two days after
challenge.
In the part III, the three groups of 70M adjuvant vac-
cine, 70M2 adjuvant vaccine and 70M6 adjuvant vac-
cines provided 100% protect to chickens with no virus
shedding, no sick sign, no dead post-challenge. How-
ever, all other vaccine groups cannot provide complete
protection to SPF chickens and also there were virus
shedding, sick sign, and even death of birds among
these groups. The chickens from mock group were all
dead within two days after challenge (Table 3).
Discussion
An effective vaccine needs not only good antigens but
also preferable adjuvant to enhance the immunogenicity
of antigen. The adjuvant was used to enhance humoral
and cellular immune responses, but adjuvant would also
lead to side-effect to bodies, such as inflammation, tis-
sue damage and pain [10]. Oil emulsion vaccine could
Figure 3 Antibody responses to 70M-ajuvanted or 70Mi-adjuvanted rH5N3 vaccines in SPF chickens.
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promote antibody titre and extend immunity period.
However, mineral oil long term stand at the injection
site, and caused inflammation and local tissue necrosis,
lead commercial value of the birds lower.
In present experiment, mineral oil, 70M, and 206
adjuvant were used to evaluate adjuvant effects. 70M
adjuvant and 206 adjuvant were oil in water (W/O) and
water in oil (W/O/W) adjuvant based on purified
mineral, respectively. The previous studies showed that
the vaccine combined 70M adjuvant, Freund’s complete
adjuvant, or incomplete Freund’s adjuvant were able to
induce similar antibody responses, but 70M adjuvant
vaccine caused obviously much less inflammatory
response after inoculation [11-14]. The avian influenza
vaccine emulsified with 70M adjuvant prepared provided
a good protection to immunized chicken [15-17]. Vac-
cine conjugated 70M adjuvant induced not only
humoral immune responses, but also strong cellular
immune responses after immunizing mice [18]. 70M
and 206 adjuvant could provide the immune enhancing
effects on Eimeria acervulina vaccine [19].
In this experiment, the antibodies of SPF chicken
induced by 70M adjuvant vaccine or mineral oil adju-
vant vaccine were higher than that of protective thresh-
old two weeks post-inoculation, but 206 adjuvant
vaccine and antigen without adjuvant did not. The
antibody levels elicited by 206 adjuvant group achieved
protective threshold three weeks later and reached the
highest level after four weeks then began to decline, but
it was no longer able to provide theoretical protection
13 weeks after immunization, which is consist with por-
cine circle virus disease inactive vaccine [20]. In part I
and II experiments, the antibody titres of 70M adjuvant
group were higher than that of the mineral oil adjuvant
group, but the differences between two groups were not
significant (P > 0.05) statistically, while the two groups
showed significant differences (P < 0.01) compared to
206 adjuvant group in part I but not in part II experi-
ments. In part II, 206 adjuvant group induced the simi-
lar immune responses to 70M adjuvant group and
mineral oil adjuvant group of ducks.
We speculated that 206 adjuvant was a kind O/W
type adjuvant, it released into the lymphoid tissue
rapidly after immunization and leaded to inefficiency to
chickens, while 70M adjuvant and mineral oil adjuvant
were a type of W/O adjuvant and could be stored at the
injection site and release slowly. Another reason maybe
due to the chickens, ducks and pigs are different species,
their immune systems possessed differences leading to
the distinguishing immune responses elicited by 206
adjuvant vaccines. However, the real reason was
unknown and to be further studied.
Table 2 The HI antibody titres of chickens of Part I post-vaccination and protection efficiency post-challenge
groups The HI antibody titre(log2) p.v. a Sick/Dead/Total The HI antibody titre(log2) p.c. b
2 w 3 w 4 w 6 w 8 w 13 w
Mineral oil 5.3 7.0 8.3 8.9 8.8 8.4 0/0/10 8.8
70 M 5.6 8.2 9.8 10.7 10.2 9.0 0/0/10 9.0
206 3.5 4.8 6.2 5.9 5.6 3.8 4/6/10 8.9
rH5N3 Antigen 2.2 2.2 6.2 5.4 4.9 3.5 6/5/10 9.7
PBS 0 0 0 0 0 0 10/10/10 – c
a Presented as log2 HI titres. Antibody titres were determined by HI test in which the test serum had been diluted twofold,
b Presented as log2 HI titres. Antibody titres on 10 day p.i. were determined by HI test in which the test serum had been diluted twofold.
c Birds were died in 2 days p.c.
Table 3 The HI antibody titre of chickens in Part III post-vaccination and protection efficiency post-challenge
Groups The antibody HI titre (log2) p.v. a Virus shedding/Dead/Total The HI antibody titre(log2) p.c. b
2 w 3 w 4 w 5 w 8 w 13 w
70 M 5.3 8.1 9.5 9.9 10.5 9.2 0/0/10 9.1
70M1 0.4 1.4 2.8 5.1 5.2 3.7 5/2/10 9.4
70M2 0.9 3.8 5.9 8.3 7.5 7.3 0/0/10 8.8
70M3 0.1 0.5 2.1 4.3 5.0 3.4 5/1/10 8.4
70M4 0 0.4 0.9 3.8 4.4 3.4 6/1/10 5.9
70M5 0.2 1.3 3.4 4.8 5.5 4.1 2/1/10 6.8
70M6 0.9 5.1 7.0 9.1 8.5 7.8 0/0/10 8.1
70M7 0 1.1 3.8 5.7 5.8 4.1 6/2/10 9.3
70M8 0 0.4 2.1 3.9 4.7 2.8 2/2/10 7.9
PBS 0 0 0 0 0 0 10/10/10 – c
a, b and c are same to table 2.
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Since 70 M adjuvant induced better immune effects
to the chickens and ducks, the French Seppic com-
pany optimized 70M adjuvant and prepared eight
70M Series of adjuvant, Montanide™ ISA 70 essai Mi
(i = 1-8) adjuvants. Immunity and challenge experi-
ments to SPF chickens showed that the antibody
induced by 70M adjuvant group surpassed protective
threshold two weeks after immunization, while the
other groups were lower than that. Three weeks later,
only 70M6 adjuvant group achieved that level. All the
other vaccine groups (70 M1, 70M3-5, 70M7, and
70M8), the titres of antibody stay low from two weeks
to thirteen weeks post-vaccination, and to 13 weeks
each groups antibody titre was lower than the thresh-
old while 70M2 and 70M6 adjuvant groups antibody
levels remained at 7log2 above, 70M adjuvant group
reached to 9log2 above. 70M2 and 70M6 adjuvant
groups achieved to the highest levels of antibody at
six weeks post-immunization, and the other groups
were at eight weeks post-immunization. Challenge
experiment results showed that 70M, 70M2, and
70M6 adjuvant groups could provide 100% protection.
The results suggested that 70M adjuvant and 70M6
adjuvant groups had good effects in all groups, and
70M adjuvant group was the best one with statisti-
cally significant differences (P < 0.01) to all other
groups.
There were no visible clinical and pathological signs at
birds inoculation sites two weeks after immunization of
the 70M adjuvant vaccine, 70Mi Series adjuvant vac-
cines, and 206 adjuvant vaccines, suggesting that all
these Seppic adjuvant had smaller side reactions. 70M
adjuvant could be best as a new type of adjuvant applied
in the production of avian influenza vaccines.
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